Remove Chronic Pain Remove Clinical Trials Remove Research and Development
article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

article thumbnail

RYAH Medtech Inc. Completes Initial Shipment for Major UK-based Clinical Trial

Cannabis Law Report

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Researchers at the University of Sydney Explore CBD Treatment for Spinal Injuries

Veriheal

Research Team to Study the Impact of CBD on Spinal Injury Pain. Professor Luke Henderson is set to be the study’s lead investigator and he explains that the unfortunate truth for more than half of spinal cord injury patients is the development of chronic pain. Lambert Initiative experts have won $1.7

article thumbnail

The Top Medical Cannabis Research of 2017

MGC Pharma

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

article thumbnail

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

Enters into the Chronic Pain Market with Psychedelics. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5%

article thumbnail

Cannabis Use In Active Athletes: Behaviors Related to Subjective Effects

Puff Puff Post

. – July 8, 2019 /Canna Newswire/ – The Colorado-based Canna Research Group developed The Athlete Pain, Exercise, and Cannabis Experience (PEACE) Survey study for active adults to look beyond the stigma of cannabis use in athletes. She is the Founder & CEO of Canna Research Group. About Canna Research Group.

article thumbnail

Cannabis Use In Active Athletes: Behaviors Related to Subjective Effects

Puff Puff Post

. – July 8, 2019 /Canna Newswire/ – The Colorado-based Canna Research Group developed The Athlete Pain, Exercise, and Cannabis Experience (PEACE) Survey study for active adults to look beyond the stigma of cannabis use in athletes. She is the Founder & CEO of Canna Research Group. About Canna Research Group.